Cambridge, Mass.-based biotechnology company Biogen is cutting office space and planning layoffs after its Alzheimer’s drug Aduhelm proved unpopular with providers and insurers, the Boston Globe reported Aug. 9.
Read the full post on Becker's Hospital Review - Healthcare News
